by Alamab | Feb 24, 2020 | ALMB-0168, Home Page
INVESTIGATIONAL NEW DRUG ALMB-0168GRANTED CLINICAL TRIAL APPROVAL IN AUSTRALIA CSPC Pharmaceutical Group Limited 石 藥 集 團 有 限 公 司 (Incorporated in Hong Kong under the Companies Ordinance)(Stock Code: 1093) Hong Kong, 24 February 2020 The board of directors (the...
by Alamab | Nov 27, 2019 | ALMB-0168
SUBMISSION OF CLINICAL TRIAL APPLICATION FOR INVESTIGATIONAL FIRST-IN-CLASS NEW DRUG ALMB-0168 IN AUSTRALIA CSPC Pharmaceutical Group Limited 石 藥 集 團 有 限 公 司 (Incorporated in Hong Kong under the Companies Ordinance)(Stock Code: 1093) Hong Kong 27 November 2019 The...
by Alamab | Oct 21, 2019 | ALMB-0166, Home Page
INVESTIGATIONAL NEW DRUG ALMB-0166GRANTED CLINICAL TRIAL APPROVAL IN AUSTRALIA CSPC Pharmaceutical Group Limited 石 藥 集 團 有 限 公 司 (Incorporated in Hong Kong under the Companies Ordinance)(Stock Code: 1093) Hong Kong, 21 October 2019 The board of directors (the...
by Alamab | Oct 18, 2019 | ALMB-0168, Home Page
FIRST-IN-CLASS PRODUCT CANDIDATE ALMB-0168GRANTED RARE PEDIATRIC DISEASE DESIGNATION BY THE U.S. FDA CSPC Pharmaceutical Group Limited 石 藥 集 團 有 限 公 司 (Incorporated in Hong Kong under the Companies Ordinance)(Stock Code: 1093) Hong Kong, 18 October 2019 The board of...
by Alamab | Sep 23, 2019 | ALMB-0168
First-in-Class Product Candidate ALMB-0168Granted Orphan-Drug Designation by the U.S. FDA CSPC Pharmaceutical Group Limited 石 藥 集 團 有 限 公 司 (Incorporated in Hong Kong under the Companies Ordinance)(Stock Code: 1093) Hong Kong, 23 September 2019 The board of directors...
